New analysis suggests Aubagio® (teriflunomide) slows brain atrophy with MS
Genzyme announced that MRI data from the Phase III TEMSO study demonstrate that Aubagio® (teriflunomide) significantly slowed brain volume loss (or atrophy) vs. placebo over two years in people with relapsing multiple sclerosis. October 07, 2015